- Home
- SACH vs OPTN Comparison
SACH vs OPTN Comparison
Compare SACH & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- OPTN
- Stock Information
- Founded
- SACH 2010
- OPTN 2010
- Country
- SACH United States
- OPTN United States
- Employees
- SACH N/A
- OPTN N/A
- Industry
- SACH Real Estate Investment Trusts
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- OPTN Health Care
- Exchange
- SACH Nasdaq
- OPTN Nasdaq
- Market Cap
- SACH 61.5M
- OPTN 78.4M
- IPO Year
- SACH 2017
- OPTN 2017
- Fundamental
- Price
- SACH $1.22
- OPTN $0.42
- Analyst Decision
- SACH Buy
- OPTN Strong Buy
- Analyst Count
- SACH 2
- OPTN 3
- Target Price
- SACH $2.25
- OPTN $3.00
- AVG Volume (30 Days)
- SACH 523.0K
- OPTN 835.9K
- Earning Date
- SACH 11-14-2024
- OPTN 11-12-2024
- Dividend Yield
- SACH 19.75%
- OPTN N/A
- EPS Growth
- SACH N/A
- OPTN N/A
- EPS
- SACH N/A
- OPTN N/A
- Revenue
- SACH $10,951,064.00
- OPTN $75,672,000.00
- Revenue This Year
- SACH N/A
- OPTN $13.42
- Revenue Next Year
- SACH N/A
- OPTN $52.99
- P/E Ratio
- SACH N/A
- OPTN N/A
- Revenue Growth
- SACH N/A
- OPTN 5.13
- 52 Week Low
- SACH $1.16
- OPTN $0.32
- 52 Week High
- SACH $4.64
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- SACH 25.79
- OPTN 35.42
- Support Level
- SACH $1.35
- OPTN $0.39
- Resistance Level
- SACH $1.48
- OPTN $0.57
- Average True Range (ATR)
- SACH 0.08
- OPTN 0.05
- MACD
- SACH 0.01
- OPTN -0.00
- Stochastic Oscillator
- SACH 15.58
- OPTN 16.53
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.